New agents for TB: where will they fit in?

Professor Helen McIlerson

Inviting clinicians, pharmacists and nurses

Professor Helen McIlerson obtained her MBChB(UCT), PhD in Clinical Pharmacology, and directs the Pharmacometrics group in the Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa. Her areas of interest include describing pharmacokinetic/pharmacodynamic relationships and interactions within antituberculosis regimens, drug-drug interactions in TB/HIV co-infected patients, and optimizing dosing in neglected populations such as children and pregnant women. She heads a pharmacometrics research unit specializing in nonlinear mixed effects analysis and is involved in several ongoing projects in Southern, East and West African adults and children. These include evaluation of the associations between genetic variants, pharmacokinetics and drug effects, and involve support of investigator-initiated pharmacology research projects at the collaborating sites.